Skip to Content
  • Previous Rank55
  • Revenues ($M)$52,824
  • Revenue Percent Change8.1%
  • Profits ($M)$7,215
  • Profits Percent Change3.7%
  • Assets ($M)$171,615
  • Employees96,500
  • Market Value — as of March 31, 2017 ($M)$203,725

Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

Ian C. Read
CEO Title
Chairman & Chief Executive Officer
Health Care
HQ Location
New York, NY
Years on Fortune 500 List23

Pfizer Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$52,8248.1%
Profits ($M)$7,2153.7%
Assets ($M)$171,615-
Total Stockholder Equity ($M)$59,544-
Market Value — as of March 31, 2017 ($M)$203,725-

Profit Ratios

Profit as % of Revenues13.7%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity12.1%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.17
EPS % Change (from 2015)5.4%
EPS % Change (5 year annual rate)-1.6%
EPS % Change (10 year annual rate)-7.9%

Total Return

Total Return to Investors (2016)4.4%
Total Return to Investors (5 year, annualized)12.3%
Total Return to Investors (10 year, annualized)6.8%